Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Moderna Therapeutics
Moderna Therapeutics
Activities:
Research & Development
Cardiovascular
Digestion
Pharmaceutical
X
LinkedIn
Trending Articles
Neopac showcases latest tube, dispensing and cap innovations at Pharmapack Paris
Highlights include company’s reduced material LowPro caps and world’s smallest child resistant tube
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Indian government bans three medicines owing to health risks
Decision follows strong stand on suspending marketing of all drugs prohibited for sale in other countries, including the US, UK, EU and Australia
You need to be a subscriber to read this article.
Click here
to find out more.
Parenteral preparations: formulation challenges
Parenteral preparations are defined as solutions, suspensions, emulsions for injection or infusion, powders for injection or infusion, gels for injection and implants. They are...
Lonza’s capsule delivers acid-sensitive ingredients to the intestine
The capsule can simplify the manufacturing process to accelerate drug development and expedite first-in-human timelines
Upcoming event
BioProcess International Europe
9-12 April 2024 | Exhibition | RAI Amsterdam
See all
Related Content
Manufacturing
Moderna announces positive phase 1/2 data for vaccine against Covid-19
Moderna has shared positive phase 1/2 data for its breakthrough combination vaccine against Influenza and Covid-19
Research & Development
How serious is the Pirola strain?
Following the recent news of gradually increasing cases of the new COVID-19 variant Pirola, we sat down with Moderna's VP of Medical Affairs Cesar Sanz Rodriguez to discuss just what people can expect in the coming months
Distribution
Moderna receives positive opinion from the EMA for Spikevax
Moderna has revealed the European Medicine's Agency (EMA) has provided positive opinion on its COVID-19 vaccine Spikevax's marketing authorisation
Research & Development
Moderna discusses mRNA technology advances
Announcements on its mRNA tech, vaccine characterisation and biodistribution were made during the company’s Science and Technology Day event
Regulatory
Moderna senior executive to speak at the ISPE conference
As Chief Technical Operations and Quality Officer, Andres is responsible for the supply of products required for the company’s preclinical and clinical development programmes
Manufacturing
Moderna and Thermo Fisher sign long-term manufacturing agreement
Thermo Fisher will provide dedicated capacity for fill-finish services, in addition to inspection, labelling and packaging
Manufacturing
National Resilience to manufacture mRNA for Moderna vaccine
Under the terms of the multi-year agreement, Resilience will produce mRNA for the COVID-19 vaccine at its facility in Mississauga, Ontario in Canada
Subscribe now